title: Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?
abstract: The use of quinolones in the treatment of non-serious community-acquired methicillin-resistant Staphylococcus aureus is discussed. The new C8-modified quinolones may be suitable for such treatment but controlled trials should be carried out to ensure that the pharmacokinetics are such that there is little risk of resistance developing.
authors.affiliation: Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
authors.forename: Bo
authors.initials: B
authors.lastname: Shopsin
authors.forename: Xilin
authors.initials: X
authors.lastname: Zhao
authors.forename: Barry N
authors.initials: BN
authors.lastname: Kreiswirth
authors.forename: Glenn S
authors.initials: GS
authors.lastname: Tillotson
authors.forename: Karl
authors.initials: K
authors.lastname: Drlica
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D006801:Humans; D016106:Methicillin Resistance; D015363:Quinolones / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D015363:Quinolones